Benign prostatic hyperplasia

189,494views

Benign prostatic hyperplasia

PGreen

PGreen

Cell-cell junctions
Marfan syndrome
Cellular structure and function
Development of the renal system
Mitosis and meiosis
Colorectal polyps and cancer: Pathology review
Endometrial hyperplasia and cancer: Clinical
Lung cancer
Metaplasia and dysplasia
Oral cancer
Testicular cancer
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Acute respiratory distress syndrome
Arterial disease
Asthma
Atrial septal defect
Bronchiectasis
Chronic bronchitis
Chronic venous insufficiency
Angina pectoris
Aortic valve disease
Coarctation of the aorta
Heart failure
Pneumonia
Tetralogy of Fallot
Shock
Mitral valve disease
Pericarditis and pericardial effusion
Pleural effusion
Dementia: Pathology review
Dementia: Pathology review
Dementia: Pathology review
Dementia: Pathology review
Dementia: Pathology review
Anxiety disorders: Clinical
Arteriovenous malformation
Bipolar and related disorders
Cauda equina syndrome
Seizures and epilepsy
Generalized anxiety disorder
Headaches: Pathology review
Huntington disease
Ischemic stroke
Major depressive disorder
Meningitis
Migraine
Multiple sclerosis
Panic disorder
Parkinson disease
Stroke: Clinical
Alzheimer disease
Diabetes mellitus: Pathology review
Adrenocorticotropic hormone
Chlamydia trachomatis
Cortisol
Cushing syndrome
Endometriosis
Glucagon
Glucocorticoids
Herpes simplex virus
HIV (AIDS)
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Hypothyroidism
Insulin
Pelvic inflammatory disease
Testosterone
Polycystic ovary syndrome
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Thyroid hormones
Anemia of chronic disease
Chronic leukemia
Coagulation disorders: Pathology review
Disseminated intravascular coagulation
Factor V Leiden
Hemophilia
Non-Hodgkin lymphoma
Hypocalcemia
Hypokalemia
Inflammation
Innate immune system
Introduction to the immune system
Iron deficiency anemia
Leukemias: Pathology review
Platelet disorders: Pathology review
Sickle cell disease (NORD)
Type IV hypersensitivity
Acute cholecystitis
Acute pancreatitis
Acute pyelonephritis
Alcohol-associated liver disease
Appendicitis
Autoimmune hepatitis
Biliary colic
Bowel obstruction
Chronic cholecystitis
Chronic pyelonephritis
Chronic pancreatitis
Cirrhosis
Congenital disorders: Clinical
Crohn disease
Gastroesophageal reflux disease (GERD)
Irritable bowel syndrome
Lower urinary tract infection
Nephrotic syndromes: Pathology review
Peptic ulcer
Renal failure: Pathology review
Ulcerative colitis
Urinary tract infections: Pathology review
Viral hepatitis
Acne vulgaris
Atopic dermatitis
Back pain: Pathology review
Bone disorders: Pathology review
Burns
Osteoarthritis
Osteoporosis
Paget disease of bone
Psoriasis
Rheumatoid arthritis
Skin cancer
Varicella zoster virus
Down syndrome (Trisomy 21)
Inheritance patterns
DNA damage and repair
DNA replication
Selective permeability of the cell membrane
Cell cycle
Free radicals and cellular injury
Autosomal trisomies: Pathology review
Breast cancer: Pathology review
Hypertension: Pathology review
Deep vein thrombosis
Emphysema
Endocarditis
Gas exchange in the lungs, blood and tissues
Peripheral artery disease
Pulmonary edema
Restrictive lung diseases
Stroke volume, ejection fraction, and cardiac output
Ventilation-perfusion ratios and V/Q mismatch
Cranial nerves
Migraine
Myasthenia gravis
Abnormal uterine bleeding: Clinical
Neisseria gonorrhoeae
Primary adrenal insufficiency
Benign prostatic hyperplasia
Hodgkin lymphoma
Introduction to the immune system
Celiac disease
Introduction to pharmacology
Drug administration and dosing regimens
Enzyme function
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug absorption and distribution
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Agonist, partial agonist and antagonist
Opioid antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid use disorder
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Anticoagulants: Direct factor inhibitors
Anticoagulants: Heparin
Anticoagulants: Warfarin
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Role of Vitamin K in coagulation
Vitamin B12 deficiency
Loop diuretics
Miscellaneous lipid-lowering medications
Potassium sparing diuretics
Adrenergic antagonists: Alpha blockers
Calcium channel blockers
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
Adrenergic antagonists: Beta blockers
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class III antiarrhythmics: Potassium channel blockers
Class I antiarrhythmics: Sodium channel blockers
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Positive inotropic medications
Vaccinations
Anthelmintic medications
Anti-mite and louse medications
Antimalarials
Hepatitis medications
Integrase and entry inhibitors
Antimetabolites: Sulfonamides and trimethoprim
Azoles
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Echinocandins
Herpesvirus medications
Mechanisms of antibiotic resistance
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Antihistamines for allergies
Miscellaneous antifungal medications
Androgens and antiandrogens
Aromatase inhibitors
Estrogens and antiestrogens
PDE5 inhibitors
Progestins and antiprogestins
Uterine stimulants and relaxants
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Non-corticosteroid immunosuppressants and immunotherapies
Hyperthyroidism medications
Hypoglycemics: Insulin secretagogues
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Mineralocorticoids and mineralocorticoid antagonists
Sympatholytics: Alpha-2 agonists
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Atypical antipsychotics
Atypical antidepressants
Typical antipsychotics
Lithium
Monoamine oxidase inhibitors
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Anti-parkinson medications
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Headaches: Clinical
Migraine medications
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Antigout medications
Folate (Vitamin B9) deficiency
Vitamin D
Fat-soluble vitamin deficiency and toxicity: Pathology review
Mumps virus
Measles virus
Rubella virus
Bordetella pertussis (Whooping cough)
Poliovirus
Pediatric infectious rashes: Clinical

Transcript

Watch video only

In benign prostatic hyperplasia, or BPH, prostatic refers to the prostate gland, hyperplasia means an increase in the number of cells, and benign means that these cells aren’t malignant, so they don’t invade neighboring tissues.

So, benign prostatic hyperplasia is the non-cancerous growth of the prostate gland.

This condition is common in men over 50, and is often considered a normal part of aging.

The prostate is a small gland, about the size and shape of a walnut, that sits under the bladder and in front of the rectum.

The urethra which is the tube through which urine leaves the bladder, goes through the prostate before reaching the penis.

And that part of the urethra is called the prostatic urethra.

The prostate is covered by a capsule of tough connective tissue and smooth muscle.

Beneath this layer, the prostate can be divided into a few zones.

The peripheral zone, which is the outermost posterior section, is the largest of the zone and contain about 70% of the prostate’s glandular tissue.

Moving inward, the next section is the central zone which contains about 25% of the glandular tissue as well as the ejaculatory ducts that join with the prostatic urethra.

Last, is the transitional zone, which contains around 5% of the glandular tissue as well as a portion of the prostatic urethra.

The transitional zone gets its name because it contains transitional cells which are also found in the bladder.

At the microscopic level, each of the tiny glands that make up the prostate is surrounded by a basement membrane made largely of collagen.

Sitting within that basement membrane, is a ring of cube-shaped basal cells as well as a few neuroendocrine cells interspersed throughout.

Finally, there’s an inner ring of luminal columnar cells, which are within the lumen or center of the gland. Luminal cells secrete substances into the prostatic fluid, that make it slightly alkaline that give it nutrients which nourish the sperm and help it survive in the acidic environment of the vagina.

During an ejaculation, sperm leave the testes, travel through the vas deferens, into the ejaculatory ducts, and travel through the prostatic urethra.

Smooth muscles in the prostate contract and push the prostatic fluid into the urethra where it joins the sperm as well as the semen which is the fluid that comes from the seminal vesicles.

The luminal cells also produce prostate specific antigen, or PSA, which helps to liquefy the gel-like semen after ejaculation, thereby freeing the sperm to swim.

The basal cells and luminal cells of the prostate rely on stimulation from androgens, or male sex hormones, for survival.

The androgens include testosterone, which is produced by the testicles, and dihydrotestosterone, which is produced in the prostate itself.

This androgen is produced by the prostatic enzyme 5α-reductase which converts testosterone into the more potent dihydrotestosterone.

Since androgens are steroids, so they can cross the cell membrane and bind to the androgen receptors within the cell’s nucleus.

This inhibits the apoptosis of or programmed cell death, allowing luminal and basal cells in the prostate to keep growing and multiplying.

Dihydrotestosterone is ten times more potent than testosterone because it can bind to androgen receptors much longer.

Now, after the age of 30, men produce about 1% less testosterone per year.

But for unclear reasons, 5α-reductase activity increases with age, so even with less testosterone, there could be an increase in dihydrotestosterone.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine 20th Ed" McGraw Hill / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine, 8e" McGraw Hill (2019)
  4. "Current Medical Diagnosis and Treatment 2020" McGraw Hill (2020)
  5. "Management of Benign Prostatic Hyperplasia" Annual Review of Medicine (2016)
  6. "Post-micturition dribble in men: causes and treatment" Nursing Standard (2008)
  7. "Post-micturition dribble in men: causes and treatment" Nursing Standard (2008)